Low-dose-rate irradiation by 131I versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 3, 2004, Pages 285-292

  Verwijnen, Suzanne ^a   Capello, Astrid ^a   Bernard, Bert ^a   Van Den Aardweg, Gerard ^a   Konijnenberg, Mark ^b   Breeman, Wout ^a   Krenning, Eric ^a   De Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Mallinckrodt Medical BV   (Netherlands)

Author keywords

CA20948; Clonogenic survival assay; High dose rate external beam therapy; Low dose rate radionuclide therapy; Radiosensitivity

Indexed keywords

IODINE 131;

ANIMAL CELL; ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CELL MEMBRANE; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG MEGADOSE; LOW DRUG DOSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; RAT; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; IODINE RADIOISOTOPES; MONTE CARLO METHOD; PANCREATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RATS;

EID: 3142782139     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/1084978041425098     Document Type: Article

References (39)

1. 177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy, Int J Cancer 2001;92: 628.
2. de Jong M, Breeman WA, Bernard BF, et al. Tumor uptake of the radiolabeled somatostatin analog [DOTA(0), Tyr3]octreotide is dependent on the peptide amount. Eur J Nucl Med 1999;26:693.
3. de Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 2002; 32:133.
4. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000;41:1704.
5. Achilefu S, Dorshow RB, Bugaj JE, et al. Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. Invest Radiol 2000;35:479.
6. Bernard BF, Krenning E, Breeman WA, et al. Use of the rat pancreatic CA20948 cell line for the comparison of radiolabeled peptides for receptor-targeted scintigraphy and radionuclide therapy, Nucl Med Commun 2000;21:1079.
7. Bugaj JE, Erion JL, Johnson MA, et al. Radiotherapeutic efficacy of (153)Sm-CMDTPA-Tyr(3)-octreotate in tumor-bearing rats. Nucl Med Biol 2001;28:327.
8. de Jong M, Breeman WA, Bernard BF, et al. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001;42:1841.
9. Lewis JS, Laforest R, Lewis MR, et al. Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model. Cancer Biother Radiopharm 2000;15:593.
10. Lewis JS, Wang M, Laforest R, et al. Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model. Int J Cancer 2001;94:873.
11. Vallabhajosula S, Moyer BR, Lister-James J, et al. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J Nucl Med 1996;37: 1016.
12. van Hagen PM, Breeman WA, Bernard HF, et al. Evaluation of a radiolabeled cyclic DTPA-RGD analog for tumor imaging and radionuclide therapy. Int J Cancer 2000;90:186.
13. Breeman WA, Hofland LJ, de Jong M, et al. Evaluation of radiolabeled bombesin analogs for receptor-targeted scintigraphy and radiotherapy. Int J Cancer 1999;81:658.
14. Behr TM, Behe MP. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 2002;32:97.
15. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation. Cancer Res 1999;59:1152.
16. Mantyh CR, Gates TS, Zimmerman RP, et al. Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules, and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn disease. Proc Natl Acad Sci USA 1988;85:3235.
17. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326.
18. DeNardo SJ, Burke PA, Leigh BR, et al. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother Radiopharm 2000;15:71.
19. Capello A, Krenning EP, Breeman WA, et al. Peptide receptor radionuclide therapy in vitro using [(111)In-DTPA(0)]octreotide. J Nucl Med 2003;44:98.
20. Hall EJ. Radiobiology for the radiologist, 5th ed., p. 478. Philadelphia: Lippincott Williams & Wilkins, 2000.
21. Briesmeister JF. MCNP-A general Monte Carlo N-particle transport code, version 4C, 2000.
22. Eckerman KF, Westfall RJ, Ryman JC, et al. Availability of nuclear decay data in electronic form, including beta spectra not previously published. Health Phys 1994;67:338.
23. van den Aardweg GJ, Naus NC, Verhoeven AC, et al. Cellular radiosensitivity of primary and metastatic human uveal melanoma cell lines. Invest Ophthalmol Vis Sci 2002;43:2561.
24. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 1990;82:1107.
25. 111In-DTPA-D-Phe1]octreotide. Eur J Nucl Med 1994;21:328.
26. 111In-labeled nonsulfated CCK8 analog: A peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 1999;40:2081.
27. Lewis JS, Lewis MR, Srinivasan A, et al. Comparison of four 64Cu-labeled somatostatin analogs in vitro and in a tumor-bearing rat model: Evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J Med Chem 1999; 42:1341.
28. Langmuir VK, Fowler JF, Knox SJ, et al. Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry. Med Phys 1993;20:601.
29. Buras RR, Wong JY, Kuhn JA, et al. Comparison of radioimmunotherapy and external-beam radiotherapy in colon cancer xenografts. Int J Radiat Oncol Biol Phys 1993;25:473.
30. 131iodine- labeled antibody for a colon cancer model. Cancer Res 1995;55:5811s.
31. Joiner MC, Marples B, Lambin P, et al. Low-dose hypersensitivity: Current status and possible mechanisms. Int J Radiat Oncol Biol Phys 2001;49:379.
32. Mitchell CR, Folkard M, Joiner MC. Effects of exposure to low-dose-rate (60)co gamma rays on human tumor cells in vitro. Radiat Res 2002;158:311.
33. Collis SJ, Sangar VK, Tighe A, et al. Development of a novel rapid assay to assess the fidelity of DNA double-strand-break repair in human tumor cells. Nucleic Acids Res 2002;30:E1.
34. Deacon J, Peckham MJ, Steel GG. The radioresponsiveness of human tumors and the initial slope of the cell-survival curve. Radiother Oncol 1984;2:317.
35. Ning S, Trisler K, Wessels BW, et al. Radiobiologic studies of radioimmunotherapy and external-beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 1997;80:2519.
36. Morton J, Yabuki H, Porter EA, et al. Relative biological effectiveness of 241Am relative to 192Ir for continuous low-dose-rate irradiation of BA1112 rat sarcomas. Radiat Res 1989;119:478.
37. Fowler JF. Radiobiological aspects of low-dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys 1990;18:1261.
38. Dale RG. Dose-rate effects in targeted radiotherapy. Phys Med Biol 1996;41:1871.
39. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumors with the novel radiolabeled somatostatin analog [(177)Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417.